(FLT3D835/836) domain of FLT3 and confer IL-3 independent growth to Ba/F3 cells.
In the mouse bone marrow transplantation (BMT) model, FLT3-LM induce a myeloproliferative syndrome stressing their transforming activity in vivo.
In this study we analyzed the pro-proliferative and anti-apoptotic potential of FLT3 in For personal use only. on . by guest www.bloodjournal.org From
INTRODUCTION
FLT3 is a member of the class III protein receptor tyrosine kinases (RTK) that are characterized by five immunoglobulin-like domains, a juxtamembrane (JM) and two protein tyrosine kinase (PTK) domains separated by an interkinase domain [1] [2] [3] . . FLT3-length mutations (FLT3-LM) which consist of in frame internal tandem duplications (ITD) and insertions in the JM domain of FLT3 occur in 20-25% of patients with AML [6] [7] [8] . These mutations have a variable length, result in an elongated FLT3 protein with constitutive tyrosine kinase activity, and are associated with higher leukocyte counts at diagnosis 7, 9 .
In vitro studies show that FLT3-LM and a TEL-FLT3 construct transform IL-3 dependent cell lines to factor independence, and constitutively activate STAT5 and MAPK [10] [11] [12] [13] . In addition, enforced expression of FLT3-LM 14 and a TEL-FLT3 fusion protein 15 induce a myeloproliferative disease in the mouse bone marrow transplantation model and a myeloproliferation in transgenic mice, respectively.
Interestingly, FLT3ITD mutations found as secondary genetic alterations in acute promyleocytic leukemia (APL) cooperate with PML/RAR in the development of the murine APL phenotype 16 .
Primary AML blasts harboring FLT3-LM were selectively sensitive to the growth inhibitory activity of the PTK inhibitor AG1295 compared to FLT3-LM negative blasts 17 . These findings underline the pathogenetic relevance of the transforming FLT3 mutations for the malignant phenotype of AML blasts. The clinical relevance of the For personal use only. on . by guest www.bloodjournal.org From 4 FLT3-LM has been demonstrated in several studies in which the presence of the FLT3-LM was associated with a worse clinical outcome 6, 7, 18, 19 . In addition, a recent CALGB study shows that genomic loss of the residual FLT3WT allele occurring in 30-35% of FLT3-LM patients further impairs the prognosis of FLT3-LM+ AML 20 .
Recently, mutations at codon D835/836 in the activation loop of FLT3 were described in 7% of AML patients [21] [22] [23] . The position D835 of FLT3 corresponds to position D816 of KIT that is mutated in patients with mastocytosis and AML. In addition to these mutations we have identified a new recurrent FLT3 mutation with transforming potential in AML patients that is generated by an insertion of two amino acids between codons 840 and 841 (FLT3-840GS) 24 .
In the present study, we identified the small molecule PTK inhibitor SU5614 as an inhibitor of the mutated and wildtype FLT3 receptor tyrosine kinase that induces growth arrest and apoptosis in FLT3 transformed cells and AML-derived cell lines expressing a constitutively activated FLT3. These findings have important implications for clinical studies with this class of PTK inhibitors in AML.
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MATERIALS AND METHODS
Screening for the LM and D835/836 mutations in the FLT3 gene: Analysis of D835/836 mutations was performed using the restriction fragment gene length polymorphism at codon 835/836 exactly as described previously 21 . After amplification of a 114 bp fragment from exon 20 using genomic DNA, PCR-products were digested by EcoRV and separated on a 8% polyacrylamide gel. Undigested bands were cut out from the gel, purified with a Qiaquick gel extraction kit and directly sequenced on a DNA-sequencer (ABI377) using a BigDye terminator cycle sequencing kit. Screening for FLT3-LM was performed as described by Nakao et al.
25
.
Reagents and cell lines:
Recombinant murine IL-3 and recombinant human FL were purchased from Biosource International (Camarillo, CA, USA) and R&D Systems (Minneapolis, MN, USA), respectively. Restriction enzymes were obtained from New England Biolabs (Beverly, MA) and reagents for PCR were purchased from Applied Biosystems (Foster City, CA). All cell lines were obtained from the DSMZ (Braunschweig, Germany) or the ATCC (Manassas, USA) and were cultured according to the suppliers instructions. Low passage murine Ba/F3 cells were obtained from the DSMZ (Braunschweig, Germany) and were maintained in RPMI-1640 medium with 10% fetal bovine serum and 10% WEHI conditioned medium as a source of murine IL-3 when indicated. The PTK-inhibitors SU5614 and SU1498 were obtained from Calbiochem (Calbiochem-Novabiochem, Bad Soden, Germany), dissolved in DMSO at stock concentrations of 10mM and 50mM, aliquoted and stored at -20°C. STI571 was kindly provided by Novartis (Basel, Switzerland After 96h absorbance at 570nm was measured using 690nm as reference wavelength in an OptiMax microplate reader (Molecular devices, Ismaning/Munich, Germany).
Cell cycle and apoptosis analysis: Cell cycle analyses were performed by determination of the DNA content of cell nuclei with propidium iodide as described For personal use only. on April 9, 2017. by guest www.bloodjournal.org From
The FLT3ITD and D835Y receptor mutants activate STAT5 and MAPK
In order to identify common signaling pathways that specifically transduce the transforming signals of the FLT3ITD and FLT3D835 receptor, we analyzed the activity of these mutants to activate STAT3, STAT5 and MAPK. Using phosphospecific antibodies, we found that both the FLT3ITD and D835Y mutants induced a strong activation of STAT5 and MAPK, but only weak activation of STAT3, and no detectable activation of AKT ( Figure 1C ). These data demonstrate that STAT5 and MAPK are common targets of the FLT3ITD and D835 mutants. Genomic DNA was analyzed in a 2% agarose gel .
D.
Cell cycle analyses were performed by determination of the DNA content with propidium iodide. Cells were stained with propidium iodide and cell nuclei were analyzed by flow cytometry. *, p<0.05; **, p<0.01; ***, p<0.001 according to student t-test comparing the percentage of cells in G0/G1, S-phase and G2M phase in untreated vs. inhibitor treated samples. A. Ba/F3 cells expressing FLT3ITD-NPOS were incubated for 6 hours with the indicated concentrations of SU5614 and protein lysates were immunoprecipitated with FLT3 antibody. Precipitates were analyzed by Western-blot.
B.
Ba/F3 cells expressing FLT3ITD-NPOS were incubated for the indicated time intervals with SU5614 at a concentration of 1µM. Protein lysates were subjected to SDS-PAGE and after blotting membranes were incubated with the indicated antibodies.
C. Lysates were prepared as described in A. and membranes were probed with phospho-specific antibodies against STAT5 and MAPK followed by specific STAT5 and MAPK antibody.
For Table 1 ). In contrast to primary AML blasts, FLT3ITD and FLT3D835 mutations were rarely found in AML cell lines and could be detected only in the AML MV4-11 cell line which carried a FLT3ITD mutation (table 1) . In addition to the For 
AML cell lines expressing an activated FLT3 receptor are selectively sensitive to the growth inhibitory activity of the FLT3 PTK inhibitor SU5614
To analyze the growth inhibitory activity of SU5614 in AML-derived cell lines, cells were incubated for up to 72h with concentrations ranging from 0.001 to 10µM of inhibitor. In proliferation assays the growth of MM1, MM6 and MV4-11 cells was selectively inhibited by SU5614 in a dose dependent manner whereas all other cell lines were completely resistant to the compound ( Figure 6 , Table 1 ). The IC 50 for the growth inhibitory activity was 300-600nM in sensitive cells which was slightly higher compared to the IC 50 in Ba/F3-FLT3ITD/D835Y cells (Table 1) . To precisely calculate the IC 50 of SU5614 against the most commonly found type of FLT3 mutation in clinical AML samples, we analyzed the MV4-11 cell line expressing a FLT3ITD mutant in detail over a wide range of inhibitor concentrations. These analyses showed that SU5614 inhibits the FLT3ITD mutant with an IC 50 of 150nM ( Figure 6C ).
The IC 50 for SU5614 calculated from the growth-response curve using a MTT assay (150nM) differed slightly from the IC 50 calculated from cell counting experiments (300nM). This difference might be due to a more precise estimation of the IC 50 
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MTT assay in which inhibitor concentrations closely covering the range between 0.01 and 1µM were used. However, it might also be attributable to the different assay systems. To further exclude that the inhibition of other kinases than FLT3 by SU5614 might contribute to the cytotoxic activity in AML cell lines, we analyzed the growth inhibitory effects of other PTK inhibitors known not to inhibit FLT3 in these cells. For this purpose we used the PTK inhibitors STI571 and SU1498 which inhibit the PDGF-R, KIT, ABL, ARG 29 and VEGF-R2, respectively 30 . As shown in Figure 6D SU5614, but not STI571 or SU1498 has significant growth inhibitory activity in MV4-11 and MM6
cells. In addition, neither SU1498 nor STI571 significantly inhibited the growth of Ba/F3 cells expressing a FLT3ITD mutant (data not shown).
To allow a direct comparison of the inhibitory activity of SU5614 against a broader range of protein tyrosine kinases, the IC 50 values calculated for FLT3 were compared with the IC 50 for receptor and nonreceptor tyrosine kinases ( For
SU5614 induces apoptotic cell death and cell cycle arrest in AML cell lines expressing an activated FLT3-receptor
To further evaluate the mechanisms of SU5614-induced growth arrest, we analyzed the potential of the compound to directly induce apoptotic cell death. The exposure of MM1, MM6 and MV4-11 cells to SU5614 for 48h resulted in the rapid induction of apoptotic cell death as determined by annexinV/7-AAD staining and the appearance For personal use only. on April 9, 2017. by guest www.bloodjournal.org From of hypodiploid DNA after staining of cell nuclei with propidium iodide (PI). A typical experiment is shown in Figure 7A (annexinV -7AAD staining) and in Figure 7B Figure 8C ). Equal loading of all lanes was confirmed after reblotting with an antibody against -actin. A. MM6 cells expressing a constitutive active FLT3 were incubated for three hours with the indicated concentrations of SU5614 and protein lysates were immunoprecipitated with FLT3 antibody. Precipitates were subjected to SDS-PAGE and after blotting membranes were incubated with PY antibody. Blots were stripped and probed with FLT3 antibody.
B. MM6 cells were incubated for 3h with SU5614. Protein lysates were subjected to SDS-PAGE and after blotting membranes were probed with phospho-specific antibodies against STAT3, STAT5 and MAPK followed by reblotting with specific STAT3 and STAT5 antibodies. Figure 9B ). In the absence of FL and serum, OCI-AML5 cells rapidly undergo apoptotic cell death whereas FL at a concentration of 100ng/ml significantly increased cell viability ( Figure   9A ). The parallel incubation of OCI-AML5 cells with FL and SU5614 completely inhibited the pro-proliferative and anti-apoptotic activity of FL in these cells over a time period of four days. As shown in figure 9C , the stimulation of serum-starved OCI-AML5 cells with FL strongly induces tyrosine phosphorylation of FLT3 which is completely inhibited by SU5614 at a concentration of 1µM.
Taken together these data clearly show that in addition to FLT3ITD and FLT3D835Y SU5614 has potent inhibitory activity against the FLT3WT kinase. . We report that SU5614 has inhibitory activity against FLT3 and induces growth arrest and apoptosis in AML blasts endogenously expressing an activated FLT3 receptor. Moreover, the compound reverts the anti-apoptotic and proproliferative activity of FL in FL-dependent cells.
Although SU5614 has a broader spectrum of inhibitory activity for other PTK, the specificity of SU5614 against FLT3 in our study is supported by the following findings: For personal use only. on April 9, 2017. by guest www.bloodjournal.org From
